Time points at which MRD is considered a clinically relevant biomarker. The time points and MRD cutoffs are indicated at which an MRD result may influence the therapeutic decision for a given patient. For example, in a patient with AML carrying an NPM1 mutation, who is monitored by qPCR, MRD persistence at ≥2% NPM1 mutant copies/ABL1 copies at the end of chemotherapy may trigger the decision to consider allo-HCT for this patient. *After 2 cycles of chemotherapy (either 2 induction cycles or 1 induction and 1 consolidation cycle), which includes the time point before allo-HCT. **Percentage NPM1 mutant copies per ABL1 copies measured in BM. ^***Log reduction of the ratio of target copies/ABL1 copies between the sample at diagnosis and the sample at end of treatment, measured in the same tissue (preferably BM).